Liver involvement in Gaucher disease in children: A literature review and clinical observations (original) (raw)

The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Veltischev Research and Clinical Institute for Pediatrics and Pediatric Surgery — Pirogov Russian National Research Medical University Ministry of Health of the Russian Federation;
Pirogov Russian National Research Medical University Ministry of Health of the Russian Federation

Movsisyan G.B.

National Medical Research Center for Children’s Health Ministry of Health of the Russian Federation

Potapov A.S.

National Medical Research Center for Children’s Health;
Sechenov First Moscow State Medical University (Sechenov University)

Khavkin A.I.

Research and Clinical Institute of Childhood Ministry of Health of the Moscow Region

Nikitin A.V.

Veltischev Research and Clinical Institute for Pediatrics and Pediatric Surgery — Pirogov Russian National Research Medical University Ministry of Health of the Russian Federation

Skvortsova T.A.

Veltischev Research and Clinical Institute for Pediatrics and Pediatric Surgery — Pirogov Russian National Research Medical University Ministry of Health of the Russian Federation

Morozova E.A.

Sechenov First Moscow State Medical University Ministry of Health of the Russian Federation (Sechenov University)

Rogozhina V.M.

Sechenov First Moscow State Medical University Ministry of Health of the Russian Federation (Sechenov University)

Liver involvement in Gaucher disease in children: A literature review and clinical observations

Authors:

Volynets G.V., Movsisyan G.B., Potapov A.S., Khavkin A.I., Nikitin A.V., Skvortsova T.A., Morozova E.A., Rogozhina V.M.

To cite this article:

Volynets GV, Movsisyan GB, Potapov AS, et al. . Liver involvement in Gaucher disease in children: A literature review and clinical observations. Russian Journal of Evidence-Based Gastroenterology. 2025;14(2):78‑93. (In Russ.)
https://doi.org/10.17116/dokgastro20251402178

Close metadata

Gaucher disease is the most prevalent lysosomal storage disorder. Although it is traditionally associated with hepatosplenomegaly, hematologic abnormalities, and skeletal involvement, hepatic involvement remains an underrecognized aspect of its clinical presentation. Liver pathology in Gaucher disease can progress to fibrosis, cirrhosis, and portal hypertension.

OBJECTIVE

To summarize current research data on liver involvement in pediatric Gaucher disease, including morphological, biochemical, and functional hepatic changes, their association with disease type, the impact of enzyme replacement therapy (ERT) on the hepatobiliary system, and to present a clinical profile of the patient based on personal clinical experience.

KEY POINTS

Liver involvement in Gaucher disease presents across a broad spectrum — from mild hepatomegaly to severe complications such as cirrhosis, portal hypertension, and hepatocellular carcinoma. Special attention should be paid to the presence of Gaucheromas — focal accumulations of Gaucher cells — which may mimic malignant tumors. Elastography, MRI, and biochemical markers do not always correlate with the degree of fibrosis. Enzyme replacement therapy significantly reduces visceral manifestations but may not fully prevent the progression of liver fibrosis, particularly in splenectomized patients. Of special interest is the neonatal cholestasis phenotype observed in type 2 Gaucher disease.

CONCLUSION

The liver is one of the major target organs in Gaucher disease. Hepatic involvement may be the first manifestation of the disorder and requires careful differential diagnosis from other chronic hepatopathies. Early initiation of enzyme replacement therapy stabilizes hepatic symptoms and improves prognosis. Management strategies should include regular liver monitoring regardless of disease stage or the presence of other complications.

Authors:

Volynets G.V.

Veltischev Research and Clinical Institute for Pediatrics and Pediatric Surgery — Pirogov Russian National Research Medical University Ministry of Health of the Russian Federation;
Pirogov Russian National Research Medical University Ministry of Health of the Russian Federation

Movsisyan G.B.

National Medical Research Center for Children’s Health Ministry of Health of the Russian Federation

Potapov A.S.

National Medical Research Center for Children’s Health;
Sechenov First Moscow State Medical University (Sechenov University)

Khavkin A.I.

Research and Clinical Institute of Childhood Ministry of Health of the Moscow Region

Nikitin A.V.

Veltischev Research and Clinical Institute for Pediatrics and Pediatric Surgery — Pirogov Russian National Research Medical University Ministry of Health of the Russian Federation

Skvortsova T.A.

Veltischev Research and Clinical Institute for Pediatrics and Pediatric Surgery — Pirogov Russian National Research Medical University Ministry of Health of the Russian Federation

Morozova E.A.

Sechenov First Moscow State Medical University Ministry of Health of the Russian Federation (Sechenov University)

Rogozhina V.M.

Sechenov First Moscow State Medical University Ministry of Health of the Russian Federation (Sechenov University)

References:

  1. Grabowski GA, Petsko GA, Kolodny EH. Part 16: Lysosomal disorders — Gaucher disease. In: Valle DL, Antonarakis S, Ballabio A, Beaudet AL, Mitchell GA, eds. The Online Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill; 2019. https://ommbid.mhmedical.com/content.aspx?bookid=2709andsectionid=225546056
  2. Gary SE, Ryan E, Steward AM, Sidransky E. Recent advances in the diagnosis and management of Gaucher disease. Expert Review of Endocrinology and Metabolism. 2018;13(2):107-118. https://doi.org/10.1080/17446651.2018.1445524
  3. Weinreb NJ, Goker-Alpan O, Kishnani PS, Longo N, Burrow TA, Bernat JA, Gupta P, Henderson N, Pedro H, Prada CE, Vats D, Pathak RR, Wright E, Ficicioglu C. The diagnosis and management of Gaucher disease in pediatric patients: Where do we go from here? Molecular Genetics and Metabolism. 2022;136(1):4-21. https://doi.org/10.1016/j.ymgme.2022.03.001
  4. Stirnemann J, Belmatoug N, Camou F, Serratrice C, Froissart R, Caillaud C, Levade T, Astudillo L, Serratrice J, Brassier A, Rose C, Billette de Villemeur T, Berger MG. A review of Gaucher disease pathophysiology, clinical presentation and treatments. International Journal of Molecular Sciences. 2017;18(2):441. https://doi.org/10.3390/ijms18020441
  5. Nalysnyk L, Rotella P, Simeone JC, Hamed A, Weinreb N. Gaucher disease epidemiology and natural history: a comprehensive review of the literature. Hematology: Transfusion and Cell Therapy. 2017;22(2):65-73. https://doi.org/10.1080/10245332.2016.1240391
  6. Sen Sarma M, Tripathi PR. Natural history and management of liver dysfunction in lysosomal storage disorders. World Journal of Hepatology. 2022;14(10):1844-1861. https://doi.org/10.4254/wjh.v14.i10.1844
  7. Grabowski GA, Antommaria AHM, Kolodny EH, Mistry PK. Gaucher disease: basic and translational science needs for more complete therapy and management. Molecular Genetics and Metabolism. 2021;132(2):59-75. https://doi.org/10.1016/j.ymgme.2020.12.291
  8. Movsisyan GB, Surkov AN, Namazova-Baranova LS, Savostyanov KV. Features of the diagnosis of Gaucher disease in children in the Russian Federation. Rossijskij zhurnal detskoj gematologii i onkologii.. 2020;7(2):42-53. (In Russ.). https://doi.org/10.21682/2311-1267-2020-7-2-42-53
  9. Mehta A, Kuter DJ, Salek SS, Belmatoug N, Bembi B, Bright J, et al. Presenting signs and patient co-variables in Gaucher disease: outcome of the Gaucher earlier diagnosis consensus (GED-C) Delphi initiative. Internal Medicine Journal. 2019;49(5):578-591. https://doi.org/10.1111/imj.14156
  10. Adar T, Ilan Y, Elstein D, Zimran A. Liver involvement in Gaucher disease — Review and clinical approach. Blood Cells, Molecules and Diseases. 2018;68:66-73. https://doi.org/10.1016/j.bcmd.2016.10.001
  11. Nascimbeni F, Dalla Salda A, Carubbi F. Energy balance, glucose and lipid metabolism, cardiovascular risk and liver disease burden in adult patients with type 1 Gaucher disease. Blood Cells, Molecules and Diseases. 2018;68:74-80. https://doi.org/10.1016/j.bcmd.2016.10.012
  12. Carubbi F, Cappellini MD, Fargion S, Fracanzani AL, Nascimbeni F. Liver involvement in Gaucher disease: A practical review for the hepatologist and the gastroenterologist. Digestive and Liver Disease. 2020;52(4):368-373. https://doi.org/10.1016/j.dld.2020.01.004
  13. Arends M, van Dussen L, Biegstraaten M, Hollak CE. Malignancies and monoclonal gammopathy in Gaucher disease: a systematic review of the literature. British Journal of Haematology. 2013;161:832-842.
  14. Nair S, Branagan AR, Liu J, Boddupalli CS, Mistry PK, Dhodapkar MV. Clonal immunoglobulin against lysolipids in the origin of myeloma. The New England Journal of Medicine. 2016;374:555-561.
  15. Regenboog M, van Dussen L, Verheij J, Weinreb NJ, Santosa D, Vom Dahl S, Häussinger D, Müller MN, Canbay A, Rigoldi M, Piperno A, Dinur T, Zimran A, Mistry PK, Salah KY, Belmatoug N, Kuter DJ, Hollak CEM. Hepatocellular carcinoma in Gaucher disease: an international case series. Journal of Inherited Metabolic Disease. 2018;41:819-827. https://doi.org/10.1007/s10545-018-0142-y
  16. Regenboog M, van Kuilenburg AB, Verheij J, Swinkels DW, Hollak CE. Hyperferritinemia and iron metabolism in Gaucher disease: potential pathophysiological implications. Blood Reviews. 2016;30:431-437.
  17. Miller A, Brown LK, Pastores GM, Desnick RJ. Pulmonary involvement in type 1 Gaucher disease: functional and exercise findings in patients with and without clinical interstitial lung disease. Clinical Genetics. 2003;63:368-376.
  18. Mistry PK, Sirrs S, Chan A, Pritzker MR, Duffy TP, Grace ME, Meeker DP, Goldman ME. Pulmonary hypertension in type 1 Gaucher’s disease: genetic and epigenetic determinants of phenotype and response to therapy. Molecular Genetics and Metabolism. 2002;77(1-2):91-98. https://doi.org/10.1016/s1096-7192(02)00122-1
  19. Saadi T, Rosenbaum H, Veitsman E, Baruch Y. Gaucher’s disease type I: a disease masked by the presence of abnormal laboratory tests common to primary liver disease. European Journal of Gastroenterology and Hepatology. 2010;22:1019-1021.
  20. vom Dahl S, Mengel E. Lysosomal storage diseases as differential diagnosis of hepatosplenomegaly. Best Practice and Research: Clinical Gastroenterology. 2010;24:619-628.
  21. Mistry PK, Sadan S, Yang R, Yee J, Yang M. Consequences of diagnostic delays in type 1 Gaucher disease: the need for greater awareness among hematologists, oncologists and an opportunity for early diagnosis and intervention. American Journal of Hematology. 2007;82:697-701.
  22. Mehta A, Belmatoug N, Bembi B, Deegan P, Elstein D, Göker-Alpan Ö, Lukina E, Mengel E, Nakamura K, Pastores GM, Pérez-López J, Schwartz I, Serratrice C, Szer J, Zimran A, Di Rocco M, Panahloo Z, Kuter DJ, Hughes D. Exploring the patient journey to diagnosis of Gaucher disease from the perspective of 212 patients with Gaucher disease and 16 Gaucher expert physicians. Molecular Genetics and Metabolism. 2017;122(3):122-129. https://doi.org/10.1016/j.ymgme.2017.08.002
  23. Lukina EA. Bolezn` Goshe (10 let spustya). M.: Prakticheskaya medicina; 2023. (In Russ.).
  24. Weinreb NJ, Goldblatt J, Villalobos J, Charrow J, Cole JA, Kerstenetzky M, vom Dahl S, Hollak C. Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment. Journal of Inherited Metabolic Disease. 2013;36(3):543-553. https://doi.org/10.1007/s10545-012-9528-4
  25. Degnan AJ, Ho-Fung VM, Ahrens-Nicklas RC, Barrera CA, Serai SD, Wang DJ, Ficicioglu C. Imaging of non-neuronopathic Gaucher disease: recent advances in quantitative imaging and comprehensive assessment of disease involvement. Insights into Imaging. 2019;10(1):70. https://doi.org/10.1186/s13244-019-0743-5
  26. Gary SE, Ryan E, Steward AM, Sidransky E. Recent advances in the diagnosis and management of Gaucher disease. Expert Review of Endocrinology and Metabolism. 2018;13(2):107-118. https://doi.org/10.1080/17446651.2018.1445524
  27. Nascimbeni F, Cassinerio E, Dalla Salda A, Motta I, Bursi S, Donatiello S, Spina V, Cappellini MD, Carubbi F. Prevalence and predictors of liver fibrosis evaluated by vibration controlled transient elastography in type 1 Gaucher disease. Molecular Genetics and Metabolism. 2018;125(1-2):64-72.
  28. Bohte AE, van Dussen L, Akkerman EM, Nederveen AJ, Sinkus R, Jansen PL, et al. Liver fibrosis in type I Gaucher disease: magnetic resonance imaging, transient elastography and parameters of iron storage. PLoS ONE. 2013;8:e57507. https://doi.org/10.1371/journal.pone.0057507
  29. Webb M, Zimran A, Dinur T, Shibolet O, Levit S, Steinberg DM, Salomon O. Are transient and shear wave elastography useful tools in Gaucher disease? Blood Cells, Molecules and Diseases. 2018;68:143-147. https://doi.org/10.1016/j.bcmd.2016.12.010
  30. Lachmann RH, Wight DG, Lomas DJ, Fisher NC, Schofield JP, Elias E, Cox TM. Massive hepatic fibrosis in Gaucher’s disease: clinico-pathological and radiological features. QJM: An International Journal of Medicine. 2000;93(4):237-244. https://doi.org/10.1093/qjmed/93.4.237
  31. Lefebvre T, Reihani N, Daher R, de Villemeur TB, Belmatoug N, Rose C, Colin-Aronovicz Y, Puy H, Le Van Kim C, Franco M, Karim Z. Involvement of hepcidin in iron metabolism dysregulation in Gaucher disease. Haematologica. 2018;103(4):587-596. https://doi.org/10.3324/haematol.2017.177816
  32. James SP, Stromeyer FW, Chang C, Barranger JA. Liver abnormalities in patients with Gaucher’s disease. Gastroenterology. 1981;80:126-133.
  33. Weinreb NJ, Barbouth DS, Lee RE. Causes of death in 184 patients with type 1 Gaucher disease from the United States who were never treated with enzyme replacement therapy. Blood Cells, Molecules and Diseases. 2018;68:211-217.
  34. Weinreb NJ, Deegan P, Kacena KA, Mistry P, Pastores GM, Velentgas P, et al. Life expectancy in Gaucher disease type 1. American Journal of Hematology. 2008;83:896-900.
  35. Hadas-Halpern I, Deeb M, Abrahamov A, Zimran A, Elstein D. Gaucher disease: spectrum of sonographic findings in the liver. Journal of Ultrasound in Medicine. 2010;29(5):727-733. https://doi.org/10.7863/jum.2010.29.5.727
  36. Regenboog M, Bohte AE, Somers I, van Delden OM, Maas M, Hollak CE. Imaging characteristics of focal splenic and hepatic lesions in type 1 Gaucher disease. Blood Cells, Molecules and Diseases. 2016;60:49-57.
  37. Stein P, Malhotra A, Haims A, Pastores GM, Mistry PK. Focal splenic lesions in type I Gaucher disease are associated with poor platelet and splenic response to macrophage-targeted enzyme replacement therapy. Journal of Inherited Metabolic Disease. 2010;33:769-774.
  38. Starosta RT, Pinto EVF, Dornelles AD, Cerski CTS, Alvares-da-Silva MR, Schwartz IVD. Hepatocellular carcinoma in Gaucher disease: reinforcing the proposed guidelines. Blood Cells, Molecules and Diseases. 2019;74:34-36.
  39. de Fost M, Vom Dahl S, Weverling GJ, Brill N, Brett S, Haussinger D, et al. Increased incidence of cancer in adult Gaucher disease in Western Europe. Blood Cells, Molecules and Diseases. 2006; 36:53-58.
  40. Weinreb NJ, Lee RE. Causes of death due to hematological and non-hematological cancers in 57 US patients with type 1 Gaucher disease who were never treated with enzyme replacement therapy. Critical Reviews in Oncology/Hematology. 2013;18:177-195.
  41. Soudek L, Siddiqui I, Guerin A, Sondheimer N, Inbar-Feigenberg M, Abuquteish D, Walia JS, Kamath BM, Kehar M. Liver transplantation for Gaucher disease presenting as neonatal cholestasis: Case report and literature review. Pediatric Transplantation. 2020;24(4):e13718. https://doi.org/10.1111/petr.13718
  42. Puri RD, Kapoor S, Kishnani PS, Dalal A, Gupta N, Muranjan M, Phadke SR, Sachdeva A, Verma IC, Mistry PK; Gaucher Disease Task Force. Diagnosis and Management of Gaucher Disease in India — Consensus Guidelines of the Gaucher Disease Task Force of the Society for Indian Academy of Medical Genetics and the Indian Academy of Pediatrics. Indian Pediatrics. 2018;55(2):143-153.
  43. Taddei TH, Dziura J, Chen S, Yang R, Hyogo H, Sullards C, Cohen DE, Pastores G, Mistry PK. High incidence of cholesterol gallstone disease in type 1 Gaucher disease: characterizing the biliary phenotype of type 1 Gaucher disease. Journal of Inherited Metabolic Disease. 2010;33:291-300. https://doi.org/10.1007/s10545-010-9070-1
  44. Ben Harosh-Katz M, Patlas M, Hadas-Halpern I, Zimran A, Elstein D. Increased prevalence of cholelithiasis in Gaucher disease: association with splenectomy but not with Gilbert syndrome. Journal of Clinical Gastroenterology. 2004;38:586-589.
  45. Rosenbaum H, Sidransky E. Cholelithiasis in patients with Gaucher disease. Blood Cells, Molecules and Diseases. 2002;28:21-27.
  46. Zimmermann A, Popp RA, Al-Khzouz C, Bucerzan S, Naşcu I, Leucuta D, Galle PR, Grigorescu-Sido P. Cholelithiasis in patients with Gaucher Disease type 1: risk factors and the role of ABCG5/ABCG8 gene variants. Journal of Gastrointestinal and Liver Diseases. 2016;25(4):447-455. https://doi.org/10.15403/jgld.2014.1121.254.zim
  47. Starosta RT, Vairo FPE, Dornelles AD, Basgalupp SP, Siebert M, Pedroso MLA, Cerski CTS, Álvares-da-Silva MR, Schwartz IVD. Liver involvement in patients with Gaucher disease types I and III. Molecular Genetics and Metabolism Reports. 2020;22:100564. https://doi.org/10.1016/j.ymgmr.2019.100564
  48. Pandey MK, Burrow TA, Rani R, Martin LJ, Witte D, Setchell KD, Mckay MA, Magnusen AF, Zhang W, Liou B, Köhl J, Grabowski GA. Complement drives glucosylceramide accumulation and tissue inflammation in Gaucher disease. Nature. 2017;543(7643):108-112. https://doi.org/10.1038/nature21368
  49. Saville JT, McDermott BK, Chin SJ, Fletcher JM, Fuller M. Expanding the clinical utility of glucosylsphingosine for Gaucher disease. Journal of Inherited Metabolic Disease. 2020;43(3):558-563. https://doi.org/10.1002/jimd.12192
  50. Lorenz F, Pawłowicz E, Klimkowska M, Beshara S, Bulanda Brustad A, Skotnicki AB, Wahlin A, Machaczka M. Ferritinemia and serum inflammatory cytokines in Swedish adults with Gaucher disease type 1. Blood Cells, Molecules and Diseases. 2018;68:35-42. https://doi.org/10.1016/j.bcmd.2016.10.010
  51. Koppe T, Doneda D, Siebert M, Paskulin L, Camargo M, Tirelli KM, Vairo F, Daudt L, Schwartz IV. The prognostic value of the serum ferritin in a southern Brazilian cohort of patients with Gaucher disease. Genetics and Molecular Biology. 2016;39(1):30-34. https://doi.org/10.1590/1678-4685-GMB-2015-0125
  52. Doneda D, Lopes AL, Teixeira BC, Mittelstadt SD, Moulin CC, Schwartz IV. Ghrelin, leptin and adiponectin levels in Gaucher disease type I patients on enzyme replacement therapy. Clinical Nutrition. 2015;34(4):727-731. https://doi.org/10.1016/j.clnu.2014.08.010
  53. Yoo JJ, Kim W, Kim MY, Jun DW, Kim SG, Yeon JE, Lee JW, Cho YK, Park SH, Sohn JH; the Korean Association for the Study of the Liver (KASL)-Korea Nonalcoholic fatty liver Study Group (KNSG). Recent research trends and updates on nonalcoholic fatty liver disease. Clinical and Molecular Hepatology. 2019;25(1):1-11. https://doi.org/10.3350/cmh.2018.0037
  54. Chin CY, Hsu CT, Lee CS, Chien YH, Wu JF. Monitoring of liver stiffness by transient elastography during the treatment of Gaucher disease. Pediatrics and Neonatology. 2019;60(2):221-223. https://doi.org/10.1016/j.pedneo.2018.05.002
  55. Lipiński P, Szymańska-Rożek P, Socha P, Tylki-Szymańska A. Controlled attenuation parameter and liver stiffness measurements using transient elastography by FibroScan in Gaucher disease. Molecular Genetics and Metabolism. 2020;129(2):125-131. https://doi.org/10.1016/j.ymgme.2019.10.013
  56. Serai SD, Naidu AP, Andrew Burrow T, Prada CE, Xanthakos S, Towbin AJ. Correlating liver stiffness with disease severity scoring system (DS3) values in Gaucher disease type 1 (GD1) patients. Molecular Genetics and Metabolism. 2018;123(3):357-363. https://doi.org/10.1016/j.ymgme.2017.10.013
  57. Razek A, Abdalla A, Barakat T, El-Taher H, Ali K. Assessment of the liver and spleen in children with Gaucher disease type I with diffusion-weighted MR imaging. Blood Cells, Molecules and Diseases. 2018;68:139-142.
  58. Abdel Razek AAK, Barakat T, Ali K. Assessment of liver and spleen in children with Gaucher disease type 1 with chemical shift imaging. Journal of Computer Assisted Tomography. 2019;43:183-186.
  59. Regenboog M, Bohte AE, Akkerman EM, Stoker J, Hollak CEM. Iron storage in liver, bone marrow and splenic Gaucheroma reflects residual disease in type 1 Gaucher disease patients on treatment. British Journal of Haematology. 2017;179:635-647.
  60. Parente DB, de Melo Malta FCM, de Souza Cravo R, Luiz RR, Rotman V, Perez RM, Rodrigues RS. Multiparametric magnetic resonance imaging of the liver and spleen in Gaucher disease. Abdominal Radiology (New York). 2024;49(9):3069-3077. https://doi.org/10.1007/s00261-024-04293-w
  61. Zhang YN, Fowler KJ, Ozturk A, Potu CK, Louie AL, Montes V, et al. Liver fibrosis imaging: A clinical review of ultrasound and magnetic resonance elastography. Journal of Magnetic Resonance Imaging. 2020;51(1):25-42. https://doi.org/10.1002/jmri.26716
  62. Ivanova M, Limgala RP, Changsila E, Kamath R, Ioanou C, Goker-Alpan O. Gaucheromas: When macrophages promote tumor formation and dissemination. Blood Cells, Molecules and Diseases. 2018;68:100-105. https://doi.org/10.1016/j.bcmd.2016.10.018
  63. Kaur G, Ahuja A, Vishwananthan GK, Sen A. Gaucher or pseudo-Gaucher cells. Blood Research. 2024;59(1):7. https://doi.org/10.1007/s44313-024-00005-x
  64. Mistry PK, Batista JL, Andersson HC, Balwani M, Burrow TA, Charrow J, Kaplan P, Khan A, Kishnani PS, Kolodny EH, Rosenbloom B, Scott CR, Weinreb N. Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry. American Journal of Hematology. 2017;92:929-939. https://doi.org/10.1002/ajh.24801
  65. Lukina E, Watman N, Dragosky M, Lau H, Avila Arreguin E, Rosenbaum H, Zimran A, Foster MC, Gaemers SJM, Peterschmitt MJ. Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1: final results from the Phase 2 trial. American Journal of Hematology. 2019;94:29-38. https://doi.org/10.1002/ajh.25300
  66. Shemesh E, Deroma L, Bembi B, Deegan P, Hollak C, Weinreb NJ, Cox TM. Enzyme replacement and substrate reduction therapy for Gaucher disease. Cochrane Database of Systematic Reviews. 2015;CD010324. https://doi.org/10.1002/14651858.CD010324.pub2
  67. Ayto RM, Hughes DA, Jeevaratnam P, Rolles K, Burroughs AK, Mistry PK, Mehta AB, Pastores GM. Long-term outcomes of liver transplantation in type 1 Gaucher disease. American Journal of Transplantation. 2010;10(8):1934-1939. https://doi.org/10.1111/j.1600-6143.2010.03168.x
  68. Fitilev SB, Vozzhaev AV, Shkrebneva II, Kudlay DA, Gapchenko EV, Markova OA, Borozinets AYu, Kazarov AA, Pantyushenko MS. Results of a phase I open randomized comparative crossover clinical trial to assess the safety and pharmacokinetics of Glurazyme® (imiglucerase) in comparison with the reference product in healthy volunteers. Oncohematology. 2019;14(4):73-83. (In Russ.). https://doi.org/10.17650/1818-8346-2019-14-4-73-83
  69. Sysoeva EP, Ponomarev RV, Lukina KA, Chavynchak RB, Korotkova SB, Zhilyaeva MV, Nikitina EG, Markova OA, Gapchenko EV, Shuster AM, Kudlay DA, Lukina EA. Evaluation of the efficacy and safety of the biosimilar drug Glurazyme (imiglucerase) in patients with Gaucher disease type 1. Gematologiya i transfuziologiya. 2020;65(1):8-23. (In Russ.). https://doi.org/10.35754/0234-5730-2020-65-1-8-23
  70. Lukina EA, Ponomarev RV, Salogub GN, Bezrukikh VA, Saifullina EV, Davydkin IL, Volkova SA, Shelekhova TV, Kosinova MV, Vasiliev EV, Kirillova EG, Danilova OE, Khairetdinov RK, Markova OA, Zuev EV, Borozinets AI. Results of a prospective observational study of imiglucerase biosimilar in adults with type I Gaucher disease. Terapevticheskii arkhiv. 2025;97(2):169-175. (In Russ.). https://doi.org/10.26442/00403660.2025.02.203194

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.